These experiments provide a proof of concept that targeting of the MCT-CD147-CAIX transport metabolon, either by interference with the CAIX antenna function or by disruption of the protein complex, can provide a useful tool for future tumor therapy. The gene discussed is SLC16A1; the disease is neoplasm.